Biblio

Found 359 results
[ Author(Asc)] Keyword Title Type Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
H
F. Heitz, du Bois, A., Harter, P., Lubbe, D., Kurzeder, C., Vergote, I. B., Plante, M., and Pfisterer, J., Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG., Gynecol Oncol, vol. 129, no. 3, pp. 463-6, 2013.
K. Hasegawa, Nagao, S., Yasuda, M., Millan, D., Viswanathan, A., Glasspool, R. M., Devouassoux-Shisheboran, M., Covens, A., Lorusso, D., Kurzeder, C., Kim, J. - W., Gladieff, L., Bryce, J., Friedlander, M. Leonard, and Fujiwara, K., Gynecologic Cancer InterGroup (GCIG) consensus review for clear cell carcinoma of the uterine corpus and cervix., Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S90-5, 2014.
P. Harter, Johnson, T., Berton-Rigaud, D., Park, S. - Y., Friedlander, M. Leonard, Del Campo, J. M., Shimada, M., Forget, F., Mirza, M. R., Colombo, N., Zamagni, C., Chan, J. K., Imhof, M., Herzog, T. J., O'Donnell, D., Heitz, F., King, K., Stinnett, S., Barrett, C., Jobanputra, M., Xu, C. - F., and du Bois, A., BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study., Gynecol Oncol, vol. 140, no. 3, pp. 443-9, 2016.
P. Harter, Sehouli, J., Reuss, A., Hasenburg, A., Scambia, G., Cibula, D., Mahner, S., Vergote, I. B., Reinthaller, A., Burges, A., Hanker, L., Pölcher, M., Kurzeder, C., Canzler, U., Petry, K. Ulrich, Obermair, A., Petru, E., Schmalfeldt, B., Lorusso, D., and du Bois, A., Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO., Int J Gynecol Cancer, vol. 21, no. 2, p. 295, 2011.
P. Harter, Gershenson, D., Lhomme, C., Lecuru, F., Ledermann, J. A., Provencher, D. M., Mezzanzanica, D., Quinn, M., Maenpaa, J. U., Kim, J. - W., Mahner, S., Hilpert, F., Baumann, K. H., Pfisterer, J., and du Bois, A., Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian tumors of low malignant potential (borderline ovarian tumors)., Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S5-8, 2014.
M. L. Harrison, Hoskins, P., du Bois, A., Quinn, M., Rustin, G. J. S., Ledermann, J. A., Baron-Hay, S., and Friedlander, M. Leonard, Small cell of the ovary, hypercalcemic type – analysis of combined experience and recommendation for management. A GCIG study, Gynecol Oncol, vol. 100, pp. 233-8, 2006.
M. L. Harrison, Hoskins, P., du Bois, A., Quinn, M., Rustin, G. J. S., Ledermann, J. A., Baron-Hay, S., and Friedlander, M. Leonard, Small cell of the ovary, hypercalcemic type -- analysis of combined experience and recommendation for management. A GCIG study., Gynecol Oncol, vol. 100, no. 2, pp. 233-8, 2006.
P. Harper, ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date., Semin Oncol, vol. 24, no. 5 Suppl 15, pp. S15-23-S15-25, 1997.
K. Harano, Hirakawa, A., Yunokawa, M., Nakamura, T., Satoh, T., Nishikawa, T., Aoki, D., Ito, K., Ito, K., Nakanishi, T., Susumu, N., Takehara, K., Watanabe, Y., Watari, H., and Saito, T., Prognostic factors in patients with uterine carcinosarcoma: a multi-institutional retrospective study from the Japanese Gynecologic Oncology Group., Int J Clin Oncol, vol. 21, no. 1, pp. 168-76, 2016.
K. Harano, Terauchi, F., Katsumata, N., Takahashi, F., Yasuda, M., Takakura, S., Takano, M., Yamamoto, Y., and Sugiyama, T., Quality-of-life outcomes from a randomized phase III trial of dose-dense weekly paclitaxel and carboplatin compared with conventional paclitaxel and carboplatin as a first-line treatment for stage II-IV ovarian cancer: JGOG Trial (JGOG3016)., Ann Oncol, vol. 25, no. 1, pp. 251-7, 2014.
L. C. Hanker, Loibl, S., Burchardi, N., Pfisterer, J., Meier, W., Pujade-Lauraine, E., Ray-Coquard, I., Sehouli, J., Harter, P., du Bois, A., ,, and Group, G. I. N. E. C. O. Study, The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy, Ann Oncol, vol. 23, pp. 2605-12, 2012.
D. Handolias, Quinn, M., Foo, S., Mileshkin, L. R., Grant, P., Dutu, G., and Rischin, D., Oral cyclophosphamide in recurrent ovarian cancer, Asia Pac J Clin Oncol, 2013.
G
I. Collaborat Group, Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial, Lancet, vol. 360, pp. 505-15, 2002.
Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial., Lancet, vol. 360, no. 9332, pp. 505-15, 2002.
B. Gronlund, Hansen, H. H., Hogdall, C., Hogdall, E. V., and Engelholm, S. A., Do CA125 response criteria overestimate tumour response in second-line treatment of epithelial ovarian carcinoma?, Br J Cancer, vol. 90, pp. 377-82, 2004.
B. Gronlund, Hogdall, E. V., Christensen, I. J., Johansen, J. S., Norgaard-Pedersen, B., Engelholm, S. A., and Hogdall, C., Pre-treatment prediction of chemoresistance in second-line chemotherapy of ovarian carcinoma: value of serological tumor marker determination (tetranectin, YKL-40, CASA, CA 125), Int J Biol Markers, vol. 21, pp. 141-8, 2006.
B. Gronlund, Hogdall, C., Hilden, J., Engelholm, S. A., Hogdall, E. V., and Hansen, H. H., Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma?, J Clin Oncol, vol. 22, pp. 4051-8, 2004.
P. Grigsby, Winter, K., Komaki, R., Marcial, V., Eifel, P. J., Doncals, D., Stevens, R., Rotman, M., and Gaffney, D. K., Long-term follow-up of RTOG 88-05: twice-daily external irradiation with brachytherapy for carcinoma of the cervix, Int J Radiat Oncol Biol Phys, vol. 54, pp. 51-7, 2002.
K. Greven, Winter, K., Underhill, K., Fontenesci, J., Cooper, J., and Burke, T., Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer, Gynecol Oncol, vol. 103, pp. 155-9, 2006.
E. Greimel, Kristensen, G. B., van der Burg, M. E. L., Coronado, P., Rustin, G. J. S., del Rio, A. Sanchez, Reed, N. Simon, Nordal, R. R., Coens, C., and Vergote, I. B., Quality of life of advanced ovarian cancer patients in the randomized phase III study comparing primary debulking surgery versus neo-adjuvant chemotherapy., Gynecol Oncol, vol. 131, no. 2, pp. 437-44, 2013.
E. Greimel, Bjelic-Radisic, V., Pfisterer, J., Hilpert, F., Daghofer, F., Pujade-Lauraine, E., du Bois, A., Group, A. Gynaekolog, and de l'Ovaire, Gd'Investig, Toxicity and quality of life outcomes in ovarian cancer patients participating in randomized controlled trials, Support Care Cancer, vol. 19, pp. 1421-7, 2011.
J. A. Green, ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit, Lancet, vol. 362, p. 1334; author reply 1334, 2003.
J. A. Green, ICON4/AGO-OVAR-2.2: questions about trial design, cost-effectiveness, and clinical benefit., Lancet, vol. 362, no. 9392, p. 1334; author reply 1334, 2003.
J. A. Green, F, D., Coens, C., S, L., Vergote, I. B., Eisenhauer, E., Bacon, M., W, C., van der Burg, M. E. L., and Oza, A. M., Prognostic value of clinical and molecular markers in advanced ovarian cancer: importance of residual disease. Translational study using tumor specimens from EORTC 55931/NCIC OV10 phase III randomized clinical trial. , Proc Am Soc Clin Oncol , vol. 23, no. 16S Part 1, 2005.
C. Gourley, Farley, J., Provencher, D. M., Pignata, S., Mileshkin, L. R., Harter, P., Maenpaa, J. U., Kim, J. - W., Pujade-Lauraine, E., Glasspool, R. M., Ray-Coquard, I., and Gershenson, D., Gynecologic Cancer InterGroup (GCIG) consensus review for ovarian and primary peritoneal low-grade serous carcinomas., Int J Gynecol Cancer, vol. 24, no. 9 Suppl 3, pp. S9-13, 2014.

Pages